当前位置: X-MOL 学术Colorectal Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer
Colorectal Disease ( IF 3.4 ) Pub Date : 2024-02-16 , DOI: 10.1111/codi.16908
Jorge Arredondo 1, 2 , Ana Almeida 1 , Carmen Castañón 3 , Carlos Sánchez 1, 2 , Amaya Villafañe 4 , Patricia Tejedor 5 , Vicente Simó 6 , Jorge Baixauli 1, 2 , Javier Rodríguez 2, 7 , Carlos Pastor 8
Affiliation  

Colon cancer (CC) is a public health concern with increasing incidence in younger populations. Treatment for locally advanced CC (LACC) involves oncological surgery and adjuvant chemotherapy (AC) to reduce recurrence and improve overall survival (OS). Neoadjuvant chemotherapy (NAC) is a novel approach for the treatment of LACC, and research is underway to explore its potential benefit in terms of survival. This trial will assess the efficacy of NAC in LACC.

中文翻译:

ELECLA 试验:关于局部晚期结肠癌新辅助治疗结果的多中心随机对照试验

结肠癌(CC)是一个公共健康问题,在年轻人中发病率不断增加。局部晚期 CC (LACC) 的治疗包括肿瘤手术和辅助化疗 (AC),以减少复发并提高总生存期 (OS)。新辅助化疗 (NAC) 是治疗 LACC 的一种新方法,目前正在进行研究以探索其在生存方面的潜在益处。该试验将评估 NAC 在 LACC 中的疗效。
更新日期:2024-02-17
down
wechat
bug